Medical technology: Baxter swallows competitor Hill-Rom for $10.5 billion

Two of the largest medical technology stocks are becoming one after Hill-Rom agreed to be acquired by Baxter. Learn how to trade the deal here. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌   Med-Tech: Baxter swallows competitor Hill-Rom for $10.5 billion Dear Reader, I have been saying for a long time that the medical technology sector is home to some of the most lucrative merger opportunities. Today, I want to tell you about one of the latest U.S. med-tech megadeals: Last Thursday, Deerfield, Illinois-based Baxter International Inc. (BAX) and Chicago, Illinois-based Hill-Rom Holdings, Inc. (HRC) announced that they had reached an agreement on a takeover deal. The announcement ends a back-and-forth negotiation process that has been going on for several months. Back in July, Baxter offered $9.5 billion for Hill-Rom, or $144 for each Hill-Rom share, but Hill-Rom turned them down. Baxter Ups Its Offer Baxter has now convinced its acquisition target with a revised offer of $156 per share in cash. With just under 66 million Hill-Rom shares outstanding, the purchase price thus amounts to almost $10.5 billion. Including debt, the total enterprise value of Hill-Rom is actually around $12.4 billion. Baxter will pay for the purchase with a combination of cash and fully committed debt. Stock Prices Jump Following the announcement of the takeover on Sept. 2, 2021, the share prices of both companies rose significantly. The price of Hill-Rom shares jumped 4.6% to $151.80. Hill-Rom shares have already gained almost 40% in the last 3 months since takeover rumors first became public. Somewhat surprisingly, however, Hill-Rom is still trading at a significant discount to Baxter’s cash offer price.   Baxter shares also gained just over 4% on Thursday, heading into the close at $81.07. Shareholders are apparently confident in the firm’s decision to acquire its smaller competitor. Baxter & Hill-Rom At A Glance Baxter is active in both the pharmaceutical and medical technology sectors. It primarily focuses on products which treat chronic medical conditions like hemophilia, chronic kidney disease and immune disorders. With a global presence, the company's approximately 50,000 employees generated $11.7 billion in sales and $1.1 billion in net income last year. Hill-Rom is also a global leader in medical technology, although it focuses less on specific kinds of treatment equipment than Baxter and more on general hospital hardware. The company's products include hospital beds, stretchers, patient monitors, operating tables and electrocardiographs. Last year, Hill-Rom's 10,000 employees generated $2.9 billion in sales with net income of $223 million. A Broader Range Of Services Baxter aims to expand its portfolio into new product lines like hospital beds with the acquisition. It also seeks to benefit from economies of scale by merging similar product lines, like monitoring equipment, with Hill-Rom. Baxter Chairman and CEO José Almeida also emphasized the synergies between the companies in his statement on the acquisition: "Baxter and Hill-Rom are joining forces to address the challenges of a rapidly evolving global healthcare landscape while creating significant value for all the stakeholders we serve." Special Offer [The New Cold War]( As the U.S.-China trade war rages, companies from other countries plan to step in to fill the void. Economist Garrett {NAME} has identified the country and 4 companies he believes will benefit most. [Get his new report RIGHT HERE.]( The Consolidation Of The Global Medical Technology Industry Baxter's acquisition of Hill-Rom is another step in the global consolidation of the med-tech sector. Back in 2014, for example, Ireland-based Medtronic paid a whopping $43 billion for competitor Covidien. In early 2017, Abbott Laboratories acquired St. Jude Medical, paying $25 billion for the pacemaker specialist. And last year, Siemens Healthineers announced the acquisition of U.S. cancer specialist Varian for about $16.5 billion. What’s Next The boards of directors of both companies have already unanimously approved the takeover. For the deal to go ahead, Hill-Rom shareholders must also vote in favor. Regulators must also still approve the takeover. The transaction is expected to be completed by early 2022. Enjoy your weekend, Dr. Gregor Bauer Chief Analyst, European Markets © 2021 Godesburg Financial Publishing, Inc. DISCLAIMER: COMMUNICATIONS FROM GODESBURG FINANCIAL PUBLISHING (GFP) ARE FOR EDUCATIONAL AND INFORMATIONAL PURPOSES ONLY – NOT INVESTMENT ADVICE: GFP and all the services it offers are for educational and informational purposes only and should NOT be understood to be securities-related offers or solicitations. None of GFP’s communications should be considered or used as personalized investment advice. GFP recommends that you speak with a licensed professional before making any investment decision. RESULTS PRESENTED ARE NOT NECCESSARILY TYPICAL OR VERIFIED: GFP communications may include information regarding the historical trading performance of gurus in their services (all verified by a third party), as well as testimonials of non-employees depicting profitable investments and trades that are believed to be true based on the representations of the persons providing the testimonial of their own free will. Please be aware that the claims regarding investing or trading results of non-employees are not tracked by GFP nor can they be verified. As always, past performance is not necessarily indicative of future results. Therefore, results presented in this email should NOT be considered TYPICAL. Actual results can and will vary based on everything from experience, ability, risk mitigation practices, and market volatility... to the amount of money exposed in the investment or trade. Investing and trading are speculative and carry serious risk. You may lose some, all - or possibly more - than your original investment or trade. GODESBURG FINANCIAL PUBLISHING IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER: GFP, including its owners and employees, are NOT registered as securities broker-dealers, brokers, or any sort of registered investment advisors with the U.S. Securities and Exchange Commission, any state securities regulatory authorities, or any self-regulatory organizations. GODESBURG FINANCIAL PUBLISHING EMPLOYEES MAY HOLD SECURITIES DISCUSSED: If a writer holds any securities in a communication, it will be disclosed along with the information on the potential investment or trade. HIR, its owners or employees, have not been - or ever will be - paid by the issuer of a security mentioned in our services or communications. GFP, its owners and employees are paid entirely or in part from commissions based on sales of their services to subscribers. For more information, please visit [our disclaimer page here.]( Sent to: {EMAIL} [Unsubscribe]( Godesburg Financial Publishing Inc., 251 Little Falls Drive, Wilmington, DE 19808, United States